Prader-willi Syndrome
📧 Sign up to get email alerts when something new happens for Prader-willi Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-12-09Clinical Trial Update: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) [Phase 2]
A Phase 2 open-label study of NNZ-2591 for Prader-Willi Syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-06-18Clinical Trial Update: Mitochondrial Complex I Dysfunction in PWS [Phase 2]
A Phase 2 clinical trial evaluating mitochondrial complex I dysfunction in Prader-Willi syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-10-06Clinical Trial Update: A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome [Phase 3]
Phase 3 extension study of RAD011 (cannabidiol oral solution) for Prader-Willi Syndrome has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-08-03Clinical Trial Update: An Open-Label Study of DCCR Tablet in Patients With PWS [Phase 3]
An open-label Phase 3 study of DCCR Tablet in Prader-Willi Syndrome was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-08-26Clinical Trial Update: Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome [Phase 4]
Phase 4 clinical trial of guanfacine extended release for aggression and self-injury in Prader-Willi Syndrome was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.